» Articles » PMID: 8631304

Specific Loss of Apoptotic but Not Cell-cycle Arrest Function in a Human Tumor Derived P53 Mutant

Overview
Journal EMBO J
Date 1996 Feb 15
PMID 8631304
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

The p53 tumor-suppressor gene product is frequently inactivated in malignancies by point mutation. Although most tumor-derived p53 mutants show loss of sequence specific transcriptional activation, some mutants have been identified which retain this activity. One such mutant, p53175P, is defective for the suppression of transformation in rodent cells, despite retaining the ability to suppress the growth of p53-null human cells. We now demonstrate that p53175P can induce a cell-cycle arrest in appropriate cell types but shows loss of apoptotic function. Our results therefore support a direct role of p53 transcriptional activation in mediating a cell-cycle arrest and demonstrate that such activity is not sufficient for the full apoptotic response. These data suggest that either p53 can induce apoptosis through a transcriptionally independent mechanism, a function lost by p53175P, or that this mutant has specifically lost the ability to activate genes which contribute to cell death, despite activation of genes responsible for the G1 arrest. This dissociation of the cell-cycle arrest and apoptotic activities of p53 indicates that inactivation of p53 apoptotic function without concomitant loss of growth inhibition can suffice to relieve p53-dependent tumor-suppression in vivo and thereby contribute to tumor development.

Citing Articles

Partial p53 reactivation is sufficient to induce cancer regression.

Klimovich B, Meyer L, Merle N, Neumann M, Konig A, Ananikidis N J Exp Clin Cancer Res. 2022; 41(1):80.

PMID: 35232479 PMC: 8889716. DOI: 10.1186/s13046-022-02269-6.


p53 partial loss-of-function mutations sensitize to chemotherapy.

Klimovich B, Merle N, Neumann M, Elmshauser S, Nist A, Mernberger M Oncogene. 2021; 41(7):1011-1023.

PMID: 34907344 PMC: 8837531. DOI: 10.1038/s41388-021-02141-5.


Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.

Timmerman D, Remmers T, Hillenius S, Looijenga L Int J Mol Sci. 2021; 22(10).

PMID: 34065345 PMC: 8161298. DOI: 10.3390/ijms22105377.


Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo.

Klimovich B, Stiewe T, Timofeev O Cell Cycle. 2019; 19(1):109-123.

PMID: 31749402 PMC: 6927723. DOI: 10.1080/15384101.2019.1693748.


Rapid generation and selection of Cas9-engineering TRP53 R172P mice that do not have off-target effects.

Zheng G, Zhu Q, Dong J, Lin X, Zhu C BMC Biotechnol. 2019; 19(1):74.

PMID: 31703569 PMC: 6839086. DOI: 10.1186/s12896-019-0573-z.


References
1.
Mercer W, Amin M, Sauve G, Appella E, Ullrich S, Romano J . Wild type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogene. 1990; 5(7):973-80. View

2.
Kuerbitz S, Plunkett B, Walsh W, Kastan M . Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992; 89(16):7491-5. PMC: 49736. DOI: 10.1073/pnas.89.16.7491. View

3.
Aloni-Grinstein R, Schwartz D, Rotter V . Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J. 1995; 14(7):1392-401. PMC: 398224. DOI: 10.1002/j.1460-2075.1995.tb07125.x. View

4.
Pines J . Cell cycle. p21 inhibits cyclin shock. Nature. 1994; 369(6481):520-1. DOI: 10.1038/369520a0. View

5.
Cho Y, Gorina S, Jeffrey P, Pavletich N . Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994; 265(5170):346-55. DOI: 10.1126/science.8023157. View